Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544623 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL12929039 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL12084140 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL15139555 | 0.80 | MAP3K14 (0.34) | — | |
| SCHEMBL13644052 | 0.78 | MAP3K14 (0.33) | — | |
| SCHEMBL13644057 | 0.78 | MAP3K14 (0.33) | — | |
| SCHEMBL12084609 | 0.78 | PKM (0.44) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL12929090 | 0.78 | PKM (0.44) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL12084489 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14467573 | 0.78 | MAP3K14 (0.34) | KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2374455-A2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1973543-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | KDM4E 3396/4885ALDH1A1 2356/4885MEN1 2672/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM4E 3396/4885ALDH1A1 2356/4885MEN1 2672/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KDM4E 3396/4885ALDH1A1 2356/4885MEN1 2672/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | KDM4E 3467/4885ALDH1A1 1353/4885MEN1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.